Ligand engagement / target binding kinetics

The dynamic flow in vivo, dictated by a drug's absorption, distribution, metabolism, and excretion (ADME) often prevents the free drug from reaching equilibrium conditions that are otherwise readily obtained in a test tube. In this sense, identifying and optimizing drug candidates based on equilibrium-derived parameters alone, such as affinity and potency, may not be ideal. Indeed, drug-target residence time may be a useful additional parameter as it is thought to represent a surrogate marker of drug clinical efficacy: the longer the drug occupies the receptor, the more profoundly the drug may exert its effect.
NL-OPENSCREEN aims to provide additional kinetic information to the hits identified in a submitted screen. For that, NL-OPENSCREEN has assembled ample expertise to add pharmacological texture to the screening results, by integrating ligand engagement / target binding kinetics into the various screening protocols.